Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
| ▸ | RPA1 | P27694 | 4/20 | 0.48 |
| ▸ | DHODH | Q02127 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147813 | 0.88 | MALT1 (0.48) | PTGS2MGLLMALT1CHRNA7RPA1 | |
| SCHEMBL5152084 | 0.88 | PTGS2 (0.56) | PTGS2MGLLMALT1CHRNA7RPA1 | |
| SCHEMBL5414188 | 0.87 | MGLL (0.59) | PTGS2MGLLMALT1CHRNA7RPA1 | |
| Hydrochloric Acid SCHEMBL5148839 | 0.84 | PTGS2 (0.60) | PTGS2MGLLMALT1CHRNA7RPA1 | |
| SCHEMBL5148778 | 0.83 | CHRNA7 (0.52) | PTGS2MALT1CHRNA7RPA1PTGS1 | |
| SCHEMBL5149105 | 0.81 | MALT1 (0.60) | PTGS2MGLLMALT1CHRNA7RPA1 | |
| SCHEMBL5147822 | 0.81 | CHRNA7 (0.52) | PTGS2MALT1CHRNA7RPA1PTGS1 | |
| SCHEMBL6207636 | 0.80 | MGLL (0.57) | PTGS2MGLLMALT1CHRNA7RPA1 | |
| SCHEMBL3814406 | 0.80 | PTGS2 (0.59) | PTGS2MGLLMALT1CHRNA7RPA1 | |
| SCHEMBL5148918 | 0.80 | MALT1 (0.53) | PTGS2MALT1CHRNA7RPA1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567503-B1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20040116475-A1 | Pyrazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | PTGS2 1780/4885MGLL 3793/4885MALT1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.